BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress

  As of September 30, 2017, cash and cash equivalents totaled $96.0 million.

  November 10, 2017

   · 

  9 min read
• Business

  Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results

  The Company’s net loss applicable to common shareholders for the three months ended September 30, 2017 was $8.9 million.

  November 10, 2017

   · 

  12 min read
• Business

  Aclaris Therapeutics Mourns the Passing of Board Member Richard A. Bierly

  Bierly was appointed to Aclaris Therapeutics’ board of directors on October 2015,

  November 10, 2017

   · 

  1 min read
• Business

  Sonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue Growth and Total Revenue of $4.3M

  Total revenue was $4.3 million for the second quarter as compared to $2.8 million for the same period last year.

  November 10, 2017

   · 

  15 min read
• Business

  Hackensack University Medical Center Collaborates with Novartis on Groundbreaking Pediatric Oncology Immunotherapy Program

  Hackensack Meridian Health Hackensack University Medical Center is pleased to announce participation in a groundbreaking pediatric oncology immunotherapy program, provided in collaboration with Novartis Pharma as a member of a network of certified treatment centers.

  November 10, 2017

   · 

  4 min read
• 

  Policy

  Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD

  The NDA submission is supported by multiple placebo-controlled safety and efficacy studies, as well as two long-term studies that assessed the safety of dasotraline in people with ADHD for up to one year.

  November 10, 2017

   · 

  7 min read
• Business

  BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2018

  For more detail related to the fiscal year 2018 unaudited first quarter results, please visit our web site at www.bioqual.com.

  November 10, 2017

   · 

  1 min read
• Business

  Codexis Reports Financial Results for the Third Quarter of 2017

  Total revenues for the third quarter of 2017 were $10.0 million compared with $14.9 million for the third quarter of 2016.

  November 10, 2017

   · 

  16 min read
• Business

  PSI and Cluequest Partner to Create The Ultimate Assessment Centre Experience Targeted at Today’s Changing World of Work

  PSI today announces a key strategic partnership with clueQuest to provide bespoke immersive escape room assessments for employee selection as an option for employers looking to assess for the changing world of work.

  November 10, 2017

   · 

  3 min read
• Business

  Immuno-Oncology CRO Secures Macrophage Pharma Agreement

  Macrophage Pharma’s immuno-oncology programme with Aquila will incorporate a combination of in vitro, in vivo and ex vivo analyses.

  November 10, 2017

   · 

  1 min read